BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 117 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
| Q2 2020 | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
| Q1 2020 | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
| Q4 2019 | $9,746,000 | +4677.5% | 2,825,000 | +11200.0% | 2.41% | +2388.7% |
| Q1 2019 | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% |
| Q4 2018 | $202,000 | -95.4% | 25,000 | -97.2% | 0.15% | -81.5% |
| Q4 2017 | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
| Q3 2017 | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
| Q2 2017 | $938,000 | -91.0% | 168,685 | -86.5% | 0.26% | -89.4% |
| Q1 2017 | $10,461,000 | +563.3% | 1,245,310 | +400.1% | 2.48% | +323.2% |
| Q4 2016 | $1,577,000 | -49.8% | 249,000 | -65.0% | 0.59% | -50.3% |
| Q3 2016 | $3,141,000 | +1.5% | 712,248 | +162.4% | 1.18% | -34.1% |
| Q3 2015 | $3,094,000 | – | 271,399 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |